Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 44 of 44 entries
Sorted by: Best Match Show Resources per page
Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials.

European heart journal

Guedeney P, Giustino G, Sorrentino S, Claessen BE, Camaj A, Kalkman DN, Vogel B, Sartori S, De Rosa S, Baber U, Indolfi C, Montalescot G, Dangas GD, Rosenson RS, Pocock SJ, Mehran R.
PMID: 31270529
Eur Heart J. 2019 Jul 03; doi: 10.1093/eurheartj/ehz430. Epub 2019 Jul 03.

AIMS: The effect of low-density lipoprotein cholesterol-lowering therapy with alirocumab or evolocumab on individual clinical efficacy and safety endpoints remains unclear. We aimed to evaluate the efficacy and safety of alirocumab and evolocumab in patients with dyslipidaemia or atherosclerotic...

Cite
Guedeney P, Giustino G, Sorrentino S, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2019;doi: 10.1093/eurheartj/ehz430.
Guedeney, P., Giustino, G., Sorrentino, S., Claessen, B. E., Camaj, A., Kalkman, D. N., Vogel, B., Sartori, S., De Rosa, S., Baber, U., Indolfi, C., Montalescot, G., Dangas, G. D., Rosenson, R. S., Pocock, S. J., & Mehran, R. (2019). Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. European heart journal, . https://doi.org/10.1093/eurheartj/ehz430
Guedeney, Paul, et al. "Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials." European heart journal vol. (2019). doi: https://doi.org/10.1093/eurheartj/ehz430
Guedeney P, Giustino G, Sorrentino S, Claessen BE, Camaj A, Kalkman DN, Vogel B, Sartori S, De Rosa S, Baber U, Indolfi C, Montalescot G, Dangas GD, Rosenson RS, Pocock SJ, Mehran R. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2019 Jul 03; doi: 10.1093/eurheartj/ehz430. Epub 2019 Jul 03. PMID: 31270529.
Copy Download .nbib Format: NLM
Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.

Revista espanola de cardiologia (English ed.)

Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL.
PMID: 29277234
Rev Esp Cardiol (Engl Ed). 2018 Jan;71(1):42. doi: 10.1016/j.rec.2017.11.020.

No abstract available.

Cite
Valgimigli M, Bueno H, Byrne RA, et al. Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Rev Esp Cardiol (Engl Ed). 2018;71(1):42doi: 10.1016/j.rec.2017.11.020.
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J. P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., Montalescot, G., Neumann, F. J., Petricevic, M., Roffi, M., Steg, P. G., Windecker, S., & Zamorano, J. L. (2018). Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Revista espanola de cardiologia (English ed.), 71(1), 42. https://doi.org/10.1016/j.rec.2017.11.020
Valgimigli, Marco, et al. "Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS." Revista espanola de cardiologia (English ed.) vol. 71,1 (2018): 42. doi: https://doi.org/10.1016/j.rec.2017.11.020
Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL. Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Rev Esp Cardiol (Engl Ed). 2018 Jan;71(1):42. doi: 10.1016/j.rec.2017.11.020. Spanish. PMID: 29277234.
Copy Download .nbib Format: NLM
Heart-breaking aspirin interruption.

Journal of thoracic disease

Zeitouni M, Montalescot G.
PMID: 29600015
J Thorac Dis. 2018 Jan;10(1):30-34. doi: 10.21037/jtd.2017.12.42.

No abstract available.

Cite
Zeitouni M, Montalescot G. Heart-breaking aspirin interruption. J Thorac Dis. 2018;10(1):30-34doi: 10.21037/jtd.2017.12.42.
Zeitouni, M., & Montalescot, G. (2018). Heart-breaking aspirin interruption. Journal of thoracic disease, 10(1), 30-34. https://doi.org/10.21037/jtd.2017.12.42
Zeitouni, Michel, and Montalescot, Gilles. "Heart-breaking aspirin interruption." Journal of thoracic disease vol. 10,1 (2018): 30-34. doi: https://doi.org/10.21037/jtd.2017.12.42
Zeitouni M, Montalescot G. Heart-breaking aspirin interruption. J Thorac Dis. 2018 Jan;10(1):30-34. doi: 10.21037/jtd.2017.12.42. PMID: 29600015; PMCID: PMC5863190.
Copy Download .nbib Format: NLM
Altered cardiac reserve is a determinant of exercise intolerance in sickle cell anaemia patients.

European journal of clinical investigation

Hammoudi N, Ceccaldi A, Haymann JP, Guedeney P, Nicolas-Jilwan F, Zeitouni M, Montalescot G, Lionnet F, Isnard R, Hatem SN.
PMID: 34390499
Eur J Clin Invest. 2022 Jan;52(1):e13664. doi: 10.1111/eci.13664. Epub 2021 Aug 21.

BACKGROUND: The underlying mechanisms of exercise intolerance in sickle cell anaemia (SCA) patients are complex and not yet completely understood. While latent heart failure at rest could be unmasked upon exercise, most previous studies assessed cardiac function at rest....

Cite
Hammoudi N, Ceccaldi A, Haymann JP, et al. Altered cardiac reserve is a determinant of exercise intolerance in sickle cell anaemia patients. Eur J Clin Invest. 2021;52(1):e13664doi: 10.1111/eci.13664.
Hammoudi, N., Ceccaldi, A., Haymann, J. P., Guedeney, P., Nicolas-Jilwan, F., Zeitouni, M., Montalescot, G., Lionnet, F., Isnard, R., & Hatem, S. N. (2022). Altered cardiac reserve is a determinant of exercise intolerance in sickle cell anaemia patients. European journal of clinical investigation, 52(1), e13664. https://doi.org/10.1111/eci.13664
Hammoudi, Nadjib, et al. "Altered cardiac reserve is a determinant of exercise intolerance in sickle cell anaemia patients." European journal of clinical investigation vol. 52,1 (2022): e13664. doi: https://doi.org/10.1111/eci.13664
Hammoudi N, Ceccaldi A, Haymann JP, Guedeney P, Nicolas-Jilwan F, Zeitouni M, Montalescot G, Lionnet F, Isnard R, Hatem SN. Altered cardiac reserve is a determinant of exercise intolerance in sickle cell anaemia patients. Eur J Clin Invest. 2022 Jan;52(1):e13664. doi: 10.1111/eci.13664. Epub 2021 Aug 21. PMID: 34390499.
Copy Download .nbib Format: NLM
Incidence, delays, and outcomes of STEMI during COVID-19 outbreak: Analysis from the France PCI registry.

Journal of the American College of Emergency Physicians open

Rangé G, Hakim R, Beygui F, Angoulvant D, Marcollet P, Godin M, Deballon R, Bonnet P, Fichaux O, Barbey C, Viallard L, Lesault PF, Durand E, Boiffard E, Dutheil G, Collet JP, Benamer H, Commeau P, Montalescot G, Koning R, Motreff P.
PMID: 33363285
J Am Coll Emerg Physicians Open. 2020 Nov 23; doi: 10.1002/emp2.12325. Epub 2020 Nov 23.

OBJECTIVES: The aim of this study was to assess the impact of the coronavirus disease 2019 (COVID-19) outbreak on incidence, delays, and outcomes of ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI) in France.METHODS: We analyzed...

Cite
Rangé G, Hakim R, Beygui F, et al. Incidence, delays, and outcomes of STEMI during COVID-19 outbreak: Analysis from the France PCI registry. J Am Coll Emerg Physicians Open. 2020;doi: 10.1002/emp2.12325.
Rangé, G., Hakim, R., Beygui, F., Angoulvant, D., Marcollet, P., Godin, M., Deballon, R., Bonnet, P., Fichaux, O., Barbey, C., Viallard, L., Lesault, P. F., Durand, E., Boiffard, E., Dutheil, G., Collet, J. P., Benamer, H., Commeau, P., Montalescot, G., Koning, R., & Motreff, P. (2020). Incidence, delays, and outcomes of STEMI during COVID-19 outbreak: Analysis from the France PCI registry. Journal of the American College of Emergency Physicians open, . https://doi.org/10.1002/emp2.12325
Rangé, Grégoire, et al. "Incidence, delays, and outcomes of STEMI during COVID-19 outbreak: Analysis from the France PCI registry." Journal of the American College of Emergency Physicians open vol. (2020). doi: https://doi.org/10.1002/emp2.12325
Rangé G, Hakim R, Beygui F, Angoulvant D, Marcollet P, Godin M, Deballon R, Bonnet P, Fichaux O, Barbey C, Viallard L, Lesault PF, Durand E, Boiffard E, Dutheil G, Collet JP, Benamer H, Commeau P, Montalescot G, Koning R, Motreff P. Incidence, delays, and outcomes of STEMI during COVID-19 outbreak: Analysis from the France PCI registry. J Am Coll Emerg Physicians Open. 2020 Nov 23; doi: 10.1002/emp2.12325. Epub 2020 Nov 23. PMID: 33363285; PMCID: PMC7753646.
Copy Download .nbib Format: NLM
Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRIT-SHOCK Substudy.

Journal of the American Heart Association

Schrage B, Zeymer U, Montalescot G, Windecker S, Serpytis P, Vrints C, Stepinska J, Savonitto S, Oldroyd KG, Desch S, Fuernau G, Huber K, Noc M, Schneider S, Ouarrak T, Blankenberg S, Thiele H, Clemmensen P.
PMID: 34622680
J Am Heart Assoc. 2021 Oct 19;10(20):e021150. doi: 10.1161/JAHA.120.021150. Epub 2021 Oct 08.

Background Little is known about the impact of center volume on outcomes in acute myocardial infarction complicated by cardiogenic shock. The aim of this study was to investigate the association between center volume, treatment strategies, and subsequent outcome in...

Cite
Schrage B, Zeymer U, Montalescot G, et al. Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRIT-SHOCK Substudy. J Am Heart Assoc. 2021;10(20):e021150doi: 10.1161/JAHA.120.021150.
Schrage, B., Zeymer, U., Montalescot, G., Windecker, S., Serpytis, P., Vrints, C., Stepinska, J., Savonitto, S., Oldroyd, K. G., Desch, S., Fuernau, G., Huber, K., Noc, M., Schneider, S., Ouarrak, T., Blankenberg, S., Thiele, H., & Clemmensen, P. (2021). Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRIT-SHOCK Substudy. Journal of the American Heart Association, 10(20), e021150. https://doi.org/10.1161/JAHA.120.021150
Schrage, Benedikt, et al. "Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRIT-SHOCK Substudy." Journal of the American Heart Association vol. 10,20 (2021): e021150. doi: https://doi.org/10.1161/JAHA.120.021150
Schrage B, Zeymer U, Montalescot G, Windecker S, Serpytis P, Vrints C, Stepinska J, Savonitto S, Oldroyd KG, Desch S, Fuernau G, Huber K, Noc M, Schneider S, Ouarrak T, Blankenberg S, Thiele H, Clemmensen P. Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRIT-SHOCK Substudy. J Am Heart Assoc. 2021 Oct 19;10(20):e021150. doi: 10.1161/JAHA.120.021150. Epub 2021 Oct 08. PMID: 34622680.
Copy Download .nbib Format: NLM
Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial.

American journal of cardiovascular drugs : drugs, devices, and other interventions

Lattuca B, Cayla G, Silvain J, Cuisset T, Leclercq F, Manzo-Silberman S, Saint-Etienne C, Delarche N, El Mahmoud R, Carrié D, Souteyrand G, Kerneis M, Hauguel-Moreau M, Zeitouni M, Guedeney P, Diallo A, Collet JP, Vicaut E, Montalescot G.
PMID: 34191259
Am J Cardiovasc Drugs. 2021 Nov;21(6):681-691. doi: 10.1007/s40256-021-00468-8. Epub 2021 Jun 30.

BACKGROUND: Elderly patients are at high-risk of bleeding, but are under-represented in clinical trials.OBJECTIVES: The aims were to determine the incidence and the predictive factors of bleeding and to assess the impact of bleeding on further ischemic outcomes in...

Cite
Lattuca B, Cayla G, Silvain J, et al. Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial. Am J Cardiovasc Drugs. 2021;21(6):681-691doi: 10.1007/s40256-021-00468-8.
Lattuca, B., Cayla, G., Silvain, J., Cuisset, T., Leclercq, F., Manzo-Silberman, S., Saint-Etienne, C., Delarche, N., El Mahmoud, R., Carrié, D., Souteyrand, G., Kerneis, M., Hauguel-Moreau, M., Zeitouni, M., Guedeney, P., Diallo, A., Collet, J. P., Vicaut, E., Montalescot, G. (2021). Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial. American journal of cardiovascular drugs : drugs, devices, and other interventions, 21(6), 681-691. https://doi.org/10.1007/s40256-021-00468-8
Lattuca, Benoit, et al. "Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial." American journal of cardiovascular drugs : drugs, devices, and other interventions vol. 21,6 (2021): 681-691. doi: https://doi.org/10.1007/s40256-021-00468-8
Lattuca B, Cayla G, Silvain J, Cuisset T, Leclercq F, Manzo-Silberman S, Saint-Etienne C, Delarche N, El Mahmoud R, Carrié D, Souteyrand G, Kerneis M, Hauguel-Moreau M, Zeitouni M, Guedeney P, Diallo A, Collet JP, Vicaut E, Montalescot G. Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial. Am J Cardiovasc Drugs. 2021 Nov;21(6):681-691. doi: 10.1007/s40256-021-00468-8. Epub 2021 Jun 30. PMID: 34191259.
Copy Download .nbib Format: NLM
The Enduring Legacy of Failed Revascularization Trials.

Journal of the American College of Cardiology

Dauerman HL, Tijssen JGP, Montalescot G.
PMID: 34736564
J Am Coll Cardiol. 2021 Nov 09;78(19):1886-1889. doi: 10.1016/j.jacc.2021.08.059.

No abstract available.

Cite
Dauerman HL, Tijssen JGP, Montalescot G. The Enduring Legacy of Failed Revascularization Trials. J Am Coll Cardiol. 2021;78(19):1886-1889doi: 10.1016/j.jacc.2021.08.059.
Dauerman, H. L., Tijssen, J. G. P., & Montalescot, G. (2021). The Enduring Legacy of Failed Revascularization Trials. Journal of the American College of Cardiology, 78(19), 1886-1889. https://doi.org/10.1016/j.jacc.2021.08.059
Dauerman, Harold L, et al. "The Enduring Legacy of Failed Revascularization Trials." Journal of the American College of Cardiology vol. 78,19 (2021): 1886-1889. doi: https://doi.org/10.1016/j.jacc.2021.08.059
Dauerman HL, Tijssen JGP, Montalescot G. The Enduring Legacy of Failed Revascularization Trials. J Am Coll Cardiol. 2021 Nov 09;78(19):1886-1889. doi: 10.1016/j.jacc.2021.08.059. PMID: 34736564.
Copy Download .nbib Format: NLM
Showing 37 to 44 of 44 entries